News

The study demonstrated strong clinical and statistical significance that PreHistin, when administered before and during allergy season, clearly and noticeably resulted in fewer allergy symptoms compared with placebo.

Under the terms of the agreement, pSivida will manufacture BrachySil and Beijing Med-Pharm will be responsible for clinical development, securing regulatory approval, marketing and distribution in China. pSivida

The multi-center phase I/II clinical study will evaluate Avrina, Corgentech’s NF-kappaB decoy drug candidate for the treatment of atopic dermatitis (eczema). This is the first of two planned

This trial is in addition to two other recently-announced non-US trials of the product, in ischemia applications, that have received regulatory clearance to proceed. The UK Medicines and

As a result of stroke the patient, Ian McBride, lost the use of his left arm and leg through paralysis. Although he had undergone traditional treatment for stroke

The study will compare the efficacy of recombinant human thrombin (rhThrombin) to bovine-derived thrombin and is designed to support broad product labeling for the use of rhThrombin as

Keppra (levetiracetam) is currently approved for adjunctive therapy in the treatment of partial onset seizures in adults and children aged four years of age and older with epilepsy.

The license and development agreement covers NicOx’s phase IIa compound, NCX 1020, for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory disorders. Topigen has secured

The multi-center, placebo-controlled, phase IIa trial is designed to assess the safety, tolerability and efficacy of XP19986 in patients with gastroesophageal reflux disease (GERD). The clinical trial is